Logo

Cardinal Health to Divest its Cordis Business to Hellman & Friedman for $1B

Share this

Cardinal Health to Divest its Cordis Business to Hellman & Friedman for $1B

Shots:

  • Cardinal Health signed an agreement to divest its Cordis medical device business to H&F for ~ $1B including liabilities and working capital accounts. The transaction is expected to close in the H1’ 22
  • Following the completion of the agreement- H&F will assume most of the Cordis assets and liabilities while Cardinal Health will retain full authority for lawsuits related to inferior vena cava filters in the US and Canada as well as the liability associated with it
  • Additionally- Cardinal Health plans to classify the business as held for sale and expect the pre-tax loss of up to $120M in Q3’21

 ­ Ref: PRNewswire | Image: Consultancy.in

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions